Related Experiment Videos
Heparin-induced thrombocytopenia: molecular pathogenesis.
Seon Ho Lee1, Chao Yan Liu, Gian PaoloVisentin
1Blood Research Institute, The Blood Center of Southeastern Wisconsin, Inc. Milwaukee, USA.
International Journal of Hematology
|November 15, 2002
Summary
Heparin-induced thrombocytopenia (HIT) involves antibodies against heparin and platelet factor 4 (PF4) complexes. Understanding this immune response may improve HIT diagnosis, treatment, and prevention.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Background:
- Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy.
- HIT can lead to severe arterial and/or venous thromboses (HITT).
- Patients with HIT/T typically have antibodies against heparin-platelet factor 4 (PF4) complexes.
Purpose of the Study:
- To understand the molecular basis of the immune response in HIT/T.
- To identify risk factors predisposing patients to HIT/T.
- To improve the diagnosis, treatment, and prevention of HIT/T.
Main Methods:
- Investigating the role of antibodies specific for heparin-PF4 complexes in HIT pathogenesis.
- Analyzing the immune response triggered by heparin-PF4 complexes.
- Identifying patient populations with high antibody prevalence.
Main Results:
- Antibodies against heparin-PF4 complexes are nearly universal in HIT/T patients.
- The immune response involves two normal body constituents: PF4 and heparin.
- Only a minority of antibody formers develop adverse effects.
Conclusions:
- Further understanding of the molecular basis of HIT/T is crucial.
- Identifying risk factors could prevent HIT/T.
- Improved diagnostic and therapeutic strategies are needed for HIT/T.